МЕТОДИЧЕСКИЕ РЕКОМЕНДАЦИИ. ОПРЕДЕЛЕНИЕ СТЕПЕНИ ДОСТОВЕРНОСТИ ПРИЧИННО-СЛЕДСТВЕННОЙ СВЯЗИ "НЕБЛАГОПРИЯТНАЯ ПОБОЧНАЯ РЕАКЦИЯ - ЛЕКАРСТВЕННОЕ СРЕДСТВО" (КЛАССИФИКАЦИЯ И МЕТОДЫ). Рекомендации. Федеральная служба по надзору в сфере здравоохранения и социального развития. 02.10.08

СПИСОК ЛИТЕРАТУРЫ

     1. Астахова А.В.,  Лепахин В.К., Неблагоприятные побочные реакции
и контроль безопасности лекарств, Москва, 2004 г., 200 стр.
     2. Брайцева    Е.В.,    Дис.    "Совершенствование    мониторинга
неблагоприятных  побочных реакций на лекарственные средства".  Москва,
2001 г., 150 стр.
     3. Осложнения  фармакотерапии.  Неблагоприятные  побочные реакции
лекарственных средств.  Т. I / Под ред. Д.В. Рейхарта, Литтерра, 2007,
с. 256.
     4. Кукес В.Г.  Нежелательные эффекты лекарственных  средств.  М.,
2006.
     5. Benichou C.  Ed.  Adverse drug reactions. A practical guide to
diagnosis and management. Chichester: John Wiley & Sons, 1994.
     6. Edwards I.R.,  Lindquist  M.,  Wiholm  B.E.,  et  al.  Quality
criteria for early signals of possible adverse drug reactions. Lancet,
1990; 336: 156-8.
     7. Girard M.,  Testing the methods of assessment for adverse drug
reactions. Adv. Drug React. At Pois. Rev. 1984; 4: 237-44.
     8. Inmann W.H.W.,  Monitoring for drug safety. 2nd ed. Lancaster:
MTP Press. 1986.
     9. Jones.J.K.,  Approaches  to  evaluating causation of suspected
drug reactions.  In:  Strom B.L.,  Velo G.  Ed.  Drug Epidemiology and
Postmarketing Surveillance. New York. Plenum Press. 1992; 103-13.
     10. Johnson   J.M.,   Reasonable   possibility:   causality   and
postmarketing surveillance. Drug. Inf. J., 1992; 26: 553-8.
     11. Karch   F.E.,   Lasagna   L.,   Towards    the    operational
identification  of  adverse drug reactions.  Clin.  Pharmacol.  Ther.,
1977; 21: 247-54.
     12. Kramer  M.S.,  Leventhal  J.M.,  Hutchinson T.A.,  et al.  An
algorithm for the operational assessment of adverse drug reactions. I.
Background,  description and instructions for use.  JAMA,  1979;  242:
623-31.
     13. Lake-Bakaar G.,  Scheuer P.J., Sherlock S., Hepatic reactions
associated with ketoconazole in the United Kingdom.  BMJ,  1987;  294:
419-2259.
     14. Lanctat  K.L.,  Naranjo  C.A.,  Comparison  of  the  Bayesian
approach and a simple algorithm for assessment of adverse drug events.
Clin Pharmacol. Ther., 1995; 58: 692-8.
     15. Meyboom R.H.B.,  Hekster Y.A.,  Egberts A.C.G., et al. Causal
or casual? The role of causality assessment in pharmacovigilance. Drug
Saf., 1997; 17: 374-89.
     16. Meyboom R.H.B.,  Royer  R.R.,  Causality  assessment  in  the
European Community. Pharmacoepidemiol. Drug Saf., 1992; 1: 87-97.
     17. Naranjo C.A.,  Busto U.,  Sellers E.M.,  et al.  A method for
estimating the probability of adverse drug reactions.  Clin. Pharmacol
Ther., 1981; 30: 239-45.
     18. Ronald      D.      Mann,      Elizabeth      B.     Andrews,
Pharmacovigilance/Wiley; 2 edition, 2007, р. 702.
     19. Salama    A.,    Muelier    Eckhardt    C.,   The   role   of
metabolitespecific antibodies in nomifensinedependent immune hemolytic
anemia. N. Engl. J. Med., 1985; 313: 469-74.
     20. Stricker B.H.C.,  Blok A.P.R.,  Claas F.H.J.,  et al. Hepatic
injury associated with the use of nitrofurans:  a clinico-pathological
study of 52 reported cases. Hepatology, 1988; 8: 559-606.
     21. Stricker   B.H.C.,   Blok   A.P.R.,   Claas  F.H.J.,  et  al.
Ketoconazole hepatic injury. J. Hepatol, 1986; 3: 399-406.
     22. Venuiet  J.,  Berneker  G.C.,  Ciucci A.G.  (Eds),  Assessing
causes of adverse drug reactions. Academic Press, London, 1982.
     23. WHO  Collaborating  Centre for International Drug Monitoring,
Uppsala,  Sweden.  14th  Annual  meeting  of  Participating   National
Centres, Barcelona, September 30 - October 1, 1991.